ClinicalTrials.gg
CompletedNCT05652738Updated May 16, 2023

Passive Cooling Versus Blanket-Roll III on The Myocardial Function of Asphyxiated Neonates

An interventional study of Passive cooling application and cooling using Blanket roll III in Hypoxic Encephalopathy, Birth Asphyxia and Neonatal Encephalopathy, sponsored by Alexandria University. Completed at 1 site in Egypt. Open to participants aged 1 Hour to 6 Hours. Per ClinicalTrials.gov, last updated 2023-05-16.

Sponsored by Alexandria University · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Jan 2022, registered Nov 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
1 Hour to 6 Hours
Sex
All
01

Study summary

Studying the effect of passive versus Blanket roll III modality of therapeutic hypothermia (TH)on myocardial function of asphyxiated neonates through using tissue Doppler (TD).

Read the detailed description

A clinical trial study of 100 Gestational-age-matched asphyxiated cooled neonates will divided into two groups, 50 in each group for comparison the myocardial function using passive cooling and BLANKET ROLL III as modality of TH.

02

Conditions studied

  • Hypoxic Encephalopathy
  • Birth Asphyxia
  • Neonatal Encephalopathy
  • Hypothermia, Newborn

Keywords

  • therapeutic hypothermia
  • asphyxiated neonates
  • tissue Doppler
03

In context

Hypoxia, Brain

81 studies on the registry are indexed under Hypoxia, Brain; 19 are open to participants now.

This study's enrollment of 100 is above the median of 60 across 55 interventional studies indexed under Hypoxia, Brain.

Browse Hypoxia, Brain studies →

Lead sponsor

Alexandria University is the lead sponsor of 604 studies on the registry; 140 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Hour to 6 Hours
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Evidence of perinatal/intrapartum hypoxia, as indicated by at least one of:

    • Apgar score of less than or equal to 5 at 10 minutes
    • Needing mechanical ventilation or ongoing resuscitation at 10 minutes
    • PH in cord blood gas is less than 7.00 or a base excess worse than or equal to minus 12 mmol /L on cord/arterial/venous/capillary blood gas obtained within 60 minutes of birth.
  • Evidence of moderate or severe encephalopathy.
  • Greater than or equal to 35 weeks gestational age.
  • Birth weight greater than or equal to 1800 g.
  • Able to begin cooling before 6 hours of birth.

Exclusion criteria

Exclusion Criteria:

  • Congenital cyanotic heart disease.
  • Multiple congenital anomalies.
  • Birth asphyxia's babies after start of cooling with cardiovascular instability.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
100 participants (actual)

Study arms

  • Active comparator
    Group I: (passive cooling group)

    Device: Passive cooling application

  • Placebo comparator
    Group II: (Blanket roll III cooling group)

    Device: cooling using Blanket roll III

Interventions

  • DevicePassive cooling application

    Passive cooling application for asphyxiated neonates and their effect on myocardial function and hemodynamics

  • Devicecooling using Blanket roll III

    standard care using Blanket roll III in asphyxiated neonates and their effect on myocardial function and hemodynamics

06

What researchers measure

Primary outcomes

  1. Myocardial function through using tissue Doppler (TD).

    neonatal echocardiography using a (Vivid IQ) with a (3-8 MHz) with software for Tissue Doppler imaging (TDI) , myocardial performance index and measuring velocities of different waveforms, cm/sec.

    Time frame: first 4 days of life

  2. Left ventricular function through using conventional echocardiography.

    Ejection fraction in percent .

    Time frame: first 4 days of life

Secondary outcomes

  1. Right ventricular function using conventional echocardiography

    TAPSE (tricuspid annular plane systolic excursion) in mm .

    Time frame: first 4 days of life

07

Study locations

1 site
  • Marwa Mohamed Farag
    Alexandria, 0356, Egypt
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Apr 2023, 15 months.

Of 33 non-industry interventional studies with no phase under Hypoxia, Brain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 44. This study's 15 months is below that.

Counting every sponsor, half of 33 studies reached it within 20 months; a quarter within 7 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2022
First posted
Dec 15, 2022
StartActual
Jan 20, 2022
Primary completionActual
Apr 20, 2023
CompletionActual
May 1, 2023
Last update
May 16, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05652738
Responsible party
Marwa Mohamed Farag (Primary Investigator and Lecturer in Pediatrics, Faculty of Medicine, Alexandria University) — Principal investigator
First posted
Dec 15, 2022
Start date
Jan 20, 2022
Primary completion
Apr 20, 2023
Completion
May 1, 2023
Last update
May 16, 2023

Study contacts

Reham M Wagdy, PhD
principal investigator · Faculty of medicine, Alexandria University, Egypt
Hossam M Kamel, MBChB
principal investigator · Faculty of medicine, Alexandria University, Egypt
Rasha M Adel Nasra
principal investigator · Alexandria University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion